falsefalse

Inside The Clinic: HR+/HER2- Metastatic Breast Cancer - Episode 3

Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC

,

Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of HR+/HER2- Metastatic Breast Cancer (mBC)
    EP. 2: Case Presentation: A 72-Year-Old Woman With HR+/HER2- mBC
    Now Viewing
    EP. 3: Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC
    EP. 4: Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC
    EP. 5: Case Presentation: A 56-Year-Old Woman With ER+/HER2- mBC
    EP. 6: Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC
    EP. 7: Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC
    EP. 8: Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC
    EP. 9: Remaining Unmet Needs for Patients With HR+/HER2- mBC
    EP. 10: Advice For Providers Caring for Patients With HR+/HER2- mBC

    Related Content:

    Inside The Clinic: HR+/HER2- Metastatic Breast CancerBreast Cancer
    Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
    ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC
    T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
    x